Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes

Promising Results in Phase 1 Study of Novel Menin Inhibitor for Aggressive Leukemia

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Mitochondria in health, disease, and aging

Frontiers Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia

Frontiers Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia

Targeting the undruggable: menin inhibitors ante portas

Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

Adult Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCI

Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy - ScienceDirect

Models of pediatric acute megakaryoblastic leukemia lead to new potential therapies

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet Haematology

Children, Free Full-Text

City of Hope presents pivotal clinical trial data at American Society of Hematology (ASH) conference on revumenib, a potential new targeted therapy for high-risk subtypes of acute leukemias

Acute myeloid leukemia - Wikipedia

Menin Inhibitors: Promising New Drug Treatment for Aggressive Leukemia